DK0604418T3 - Isolerede viralproteincytokinantagonister - Google Patents

Isolerede viralproteincytokinantagonister

Info

Publication number
DK0604418T3
DK0604418T3 DK91917100T DK91917100T DK0604418T3 DK 0604418 T3 DK0604418 T3 DK 0604418T3 DK 91917100 T DK91917100 T DK 91917100T DK 91917100 T DK91917100 T DK 91917100T DK 0604418 T3 DK0604418 T3 DK 0604418T3
Authority
DK
Denmark
Prior art keywords
cytokine antagonists
isolated viral
viral protein
protein cytokine
disclosed
Prior art date
Application number
DK91917100T
Other languages
Danish (da)
English (en)
Inventor
Craig A Smith
Raymond G Goodwin
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0604418T3 publication Critical patent/DK0604418T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK91917100T 1991-03-29 1991-03-29 Isolerede viralproteincytokinantagonister DK0604418T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/002207 WO1992017583A1 (en) 1991-03-29 1991-03-29 Isolated viral protein cytokine antagonists

Publications (1)

Publication Number Publication Date
DK0604418T3 true DK0604418T3 (da) 1999-06-14

Family

ID=22225427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91917100T DK0604418T3 (da) 1991-03-29 1991-03-29 Isolerede viralproteincytokinantagonister

Country Status (8)

Country Link
EP (1) EP0604418B1 (de)
JP (1) JPH06508502A (de)
AT (1) ATE171471T1 (de)
AU (1) AU646695B2 (de)
DE (1) DE69130262T2 (de)
DK (1) DK0604418T3 (de)
ES (1) ES2123515T3 (de)
WO (1) WO1992017583A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495515B1 (en) 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
PL330149A1 (en) * 1996-05-22 1999-04-26 Univ Alberta Bonding chemokins of type ii proteins and method of applying them
EP1034789A1 (de) * 1996-05-22 2000-09-13 University Of Alberta Typ-2 Chemokine-Bindende Proteine und Verfahren zu deren Verwendung
WO2000021981A2 (de) * 1998-10-09 2000-04-20 Bioserv Ag TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
US6589933B1 (en) 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
CN1253575C (zh) * 1999-11-30 2006-04-26 诺沃奇梅兹生物技术有限公司 用共有翻译起始区序列制备多肽的方法
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
EP1339737B1 (de) 2000-12-04 2007-06-13 Viron Therapeutics, Inc. Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2065346C (en) * 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors

Also Published As

Publication number Publication date
JPH06508502A (ja) 1994-09-29
AU8656991A (en) 1992-11-02
ES2123515T3 (es) 1999-01-16
EP0604418B1 (de) 1998-09-23
DE69130262D1 (de) 1998-10-29
EP0604418A1 (de) 1994-07-06
WO1992017583A1 (en) 1992-10-15
ATE171471T1 (de) 1998-10-15
DE69130262T2 (de) 1999-03-18
AU646695B2 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
ATE171471T1 (de) Isolierte virale proteine als cytokinantagonisten
ATE114169T1 (de) Morphogenetisches knochenprotein.
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
FI874706L (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
NO923953D0 (no) Peptider
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
LU90591I2 (fr) Enbrel-etanercept
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
FI894459A7 (fi) Menetelmä uusien kinolyylioksatsol-2-onien valmistamiseksi, jotka ovat käyttökelpoisia proteiinikinaasi C:n inhibiittoreina
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
SE9602822D0 (sv) New receptor
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
IT8423517A0 (it) Composizione farmaceutica per combattere infezioni virali, eprocedimento di uso per le infezioni virali.
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
SE9604439D0 (sv) New receptor
DK0579765T3 (da) Fremgangsmåde og præparat til behandling af herpes-relaterede sygdomme
NO880479D0 (no) Smaa peptider som hindrer binding til t4-reseptorer og virker som immunorganer, fremgangsmaaten til deres fremstilling og anvendelse av slike peptider.
FI810866A7 (fi) Substituoituja alkyylitioasyyliaminohappoja, niiden valmistusmenetelmiä ja farmaseuttfarmaseuttisia seoksia.